Article
Urology & Nephrology
Yiming Gong, Liancheng Fan, Xiaochen Fei, Yinjie Zhu, Xinxing Du, Yuman He, Jiahua Pan, Baijun Dong, Wei Xue
Summary: The study explored the genomic features of prostate cancer metastases in different sites, revealing distinct genetic profiles and alterations, including low AR alterations in pulmonary metastasis and high DNA damage response pathway deficiencies in hepatic metastasis. PTEN alterations were found to be more prevalent in viscerally metastatic prostate cancer. These findings suggest potential therapeutic targets in visceral metastatic prostate cancer.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Arnaud Bayle, Debora Basile, Simon Garinet, Bastien Rance, Pierre Laurent-Puig, Helene Blons, Julien Taieb, Geraldine Perkins
Summary: This study evaluated the role of NGS targeted panels in digestive oncology, showing that it allows for an exhaustive search for molecular abnormalities and provides patients with more opportunities for targeted therapies. Regular updates and further studies are needed for better analysis of prognostic factors.
Article
Urology & Nephrology
Maria Camila Suarez Arbelaez, Joseph M. Israeli, Craig D. Tipton, Justin Loloi, Nicholas Deebel, Joon Yau Leong, Ranjith Ramasamy
Summary: This study investigated the impact of vasectomy on the semen microbiome by comparing semen samples before and after the procedure. It was found that vasectomy resulted in a decrease in microbiome diversity and changes in the relative abundance of bacterial species in semen. Further research is needed to understand the clinical significance of these changes.
EUROPEAN UROLOGY FOCUS
(2023)
Article
Oncology
Min-Ying Sun, Fang-Qin Lin, Lu-Jia Chen, Hong Li, Wei-Quan Lin, Hong-Yan Du, Xue-Xi Yang, Ming Li
Summary: Liquid biopsy by detecting circulating tumor DNA (ctDNA) has potential advantages in cancer monitoring and prediction, serving as a potential biomarker for evaluation, prediction, and clinical management guidance of metastatic breast cancer patients undergoing chemotherapy. Results show that ctDNA mutation levels are associated with tumor size, HER2 status, and poor survival outcomes, indicating its potential in assessing treatment efficacy and guiding clinical decisions.
Article
Biochemistry & Molecular Biology
Thais Maloberti, Antonio De Leo, Sara Coluccelli, Viviana Sanza, Elisa Gruppioni, Annalisa Altimari, Stefano Zagnoni, Francesca Giunchi, Francesco Vasuri, Michelangelo Fiorentino, Veronica Mollica, Simona Ferrari, Sara Miccoli, Michela Visani, Daniela Turchetti, Francesco Massari, Giovanni Tallini, Dario de Biase
Summary: Despite advances in therapy, metastatic CRPC remains lethal. This study aimed to verify the effectiveness of a panel in analyzing mCRPC and mutations in BRCA1/BRCA2 and HRR genes. 50 mCRPC cases were analyzed using a multi-gene next-generation sequencing panel, and mutations were found in 46.0% of cases, with BRCA2 being the most commonly mutated gene. The panel and clinical algorithm are now used for managing mCRPC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Yueyun Ma, Wenjie Li, Shiyu Chen, Shuimiao Lin, Sijie Ding, Xiaomei Zhou, Tongxin Liu, Rong Wang, Wei Wang
Summary: In this study, a comprehensive analysis was performed on patients with advanced or metastatic esophageal cancer who underwent next-generation sequencing (NGS). Mutations in 227 genes were identified, with TP53, NQO1, DPYD, GSTM1, XRCC1 and ERCC1 being the most common. Patients who received NGS-guided therapy showed improved clinical outcomes. The study highlights the importance of NGS in precision therapy for esophageal cancer.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Aleksander Salomon-Perzynski, Joanna Barankiewicz, Marcin Machnicki, Irena Misiewicz-Krzeminska, Michal Pawlak, Sylwia Radomska, Agnieszka Krzywdzinska, Aleksandra Bluszcz, Piotr Stawinski, Malgorzata Rydzanicz, Natalia Jakacka, Iwona Solarska, Katarzyna Borg, Zofia Spyra-Gorny, Tomasz Szpila, Bartosz Pula, Sebastian Grosicki, Tomasz Stoklosa, Rafal Ploski, Ewa Lech-Maranda, Jana Jakubikova, Krzysztof Jamroziak
Summary: Tracking genetic changes during multiple myeloma progression reveals different patterns of mutation evolution, with mutation loss pathway associated with better treatment response. Many druggable genes are mutated, even in heavily pre-treated patients. Redefining R-ISS at relapse is clinically valuable.
Article
Biology
Maria Guarnaccia, Laura Guarnaccia, Valentina La Cognata, Stefania Elena Navone, Rolando Campanella, Antonella Ampollini, Marco Locatelli, Monica Miozzo, Giovanni Marfia, Sebastiano Cavallaro
Summary: The study developed a targeted next-generation sequencing approach for analyzing genetic variations and chromosomal aberrations in gliomas, which can provide accurate and specific assessment of tumor pathogenesis, prognosis, and treatment response. This has important implications for the diagnosis and treatment of gliomas.
Article
Biotechnology & Applied Microbiology
Songbai Zheng, Xiaodan Wang, Ying Fu, Beibei Li, Jianhua Xu, Haifang Wang, Zhen Huang, Hui Xu, Yurong Qiu, Yaozhou Shi, Kui Li
Summary: This study investigated genetic variations in Chinese NSCLC patients using next-generation sequencing, identifying common mutated genes and genes with copy number variation. GO and KEGG analyses revealed that these genes were mainly involved in tumor-related signaling pathways such as PI3K-Akt, FoxO, and Ras.
Article
Genetics & Heredity
Xiangyin Liu, Han Zhang, Xinyue Zhang, Hongguo Zhang, Yuting Jiang, Ruizhi Liu, Jia Fei, Ying Wang, Yang Yu
Summary: The NGS method was validated as an alternative to traditional STS-PCR method for detecting Y chromosome microdeletions in infertile men. It not only detects CNV like partial deletion or duplication, but also provides detailed information on the abnormal range and size of variations.
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
(2021)
Article
Oncology
Jian Pan, Jinou Zhao, Xudong Ni, Hualei Gan, Yu Wei, Junlong Wu, Tingwei Zhang, Qifeng Wang, Stephen J. Freedland, Beihe Wang, Shaoli Song, Dingwei Ye, Chang Liu, Yao Zhu
Summary: The study evaluated the prevalence and prognostic value of therapeutic targets (TTs) in Chinese mCRPC patients, finding that metastatic volume was an independent factor influencing TT positivity, and patients with positive PET/CT and HRR defects had shorter PFS after receiving abiraterone. Precision treatments based on specific TTs criteria could be beneficial for improving outcomes in patients with mCRPC who had poor prognosis on abiraterone.
MOLECULAR ONCOLOGY
(2022)
Article
Medical Laboratory Technology
Bennett Oh Vic Shum, Carel Jacobus Pretorius, Letitia Min Fen Sng, Ilya Henner, Paulette Barahona, Emre Basar, Jim McGill, Urs Wilgen, Anna Zournazi, Lilian Downie, Natalie Taylor, Liam Cheney, Sylvania Wu, Natalie Angela Twine, Denis Carolin Bauer, Gerald Francis Watts, Akash Navilebasappa, Kishore Rajagopal Kumar, Jacobus Petrus Johannes Ungerer, Glenn Bennett
Summary: The study found that newborn screening can be expanded using targeted gene sequencing (TGS), which is a feasible and cost-effective method. The TGS assay had a high sensitivity (>99%) and specificity (100%) with a turnaround time of 7 to 10 days and a maximum batch size of 1536 samples. This approach can increase the number of conditions screened and improve the effectiveness of newborn screening programs.
CLINICAL CHEMISTRY
(2023)
Article
Pathology
J. Lippert, S. Bonlokke, A. Utke, B. R. Knudsen, B. S. Sorensen, T. Steiniche, M. Stougaard
Summary: The study demonstrates that targeted NGS is effective in detecting and genotyping HPV in both FFPE biopsies and plasma samples. This method provides early diagnosis and prognosis for cervical cancer progression, enhancing recovery and survival potential for patients.
EXPERIMENTAL AND MOLECULAR PATHOLOGY
(2021)
Article
Immunology
Ravina Kullar, Emanuele Chisari, James Snyder, Christopher Cooper, Javad Parvizi, Jason Sniffen
Summary: This article discusses the gaps in traditional culture and introduces the utility of next-generation sequencing (NGS) in diagnosing and treating peri-prosthetic joint infections. It highlights the clinical benefits of using NGS compared to culture alone and emphasizes the potential of NGS in improving the yield of identifying infective organisms in challenging cases.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Ali Yavuz Cakir, Kuyas Hekimler Ozturk, Alper Ozorak
Summary: The study aimed to assess the prevalence of germline mutations in prostate cancer patients using a targeted NGS-based multiple gene panel. The results showed a low incidence of pathogenic/likely pathogenic variants and identified novel variants. The findings contribute to understanding the genetic pathogenesis of prostate cancer and highlight the benefits of using multigene panel-based genetic tests for genetic counseling.
TURKISH JOURNAL OF MEDICAL SCIENCES
(2022)
Review
Oncology
Vadim S. Koshkin, Vaibhav G. Patel, Alicia Ali, Mehmet A. Bilen, Deepak Ravindranathan, Joseph J. Park, Olesia Kellezi, Marcin Cieslik, Justin Shaya, Angelo Cabal, Landon Brown, Matthew Labriola, Laura S. Graham, Colin Pritchard, Abhishek Tripathi, Sanober Nusrat, Pedro Barata, Albert Jang, Shuang R. Chen, Rohan Garje, Luna Acharya, Clara Hwang, Amanda Pilling, William Oh, Tomi Jun, Divya Natesan, Chris Nguyen, Deepak Kilari, Michael Pierro, Bicky Thapa, Frank Cackowski, Alleda Mack, Elisabeth Heath, Catherine H. Marshall, Scott T. Tagawa, Susan Halabi, Michael T. Schweizer, Andrew Armstrong, Tanya Dorff, Ajjai Alva, Rana McKay
Summary: The PROMISE consortium, established by 16 academic institutions in early 2020, aims to create a powerful clinical-genomic platform to address data gaps in prostate cancer management. It provides valuable insights from underrepresented patient populations, generates new research hypotheses, and tackles challenging clinical questions.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Urology & Nephrology
Dimitrios Makrakis, Rafee Talukder, Leonidas N. Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Vadim S. Koshkin, Joseph J. Park, Ajjai Alva, Mehmet A. Bilen, Tyler F. Stewart, Rana R. McKay, Victor S. Santos, Neeraj Agarwal, Jayanshu Jain, Yousef Zakharia, Rafael Morales-Barrera, Michael E. Devitt, Michael Grant, Mark P. Lythgoe, David J. Pinato, Ariel Nelson, Christopher J. Hoimes, Evan Shreck, Benjamin A. Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgic, Ana Frobe, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson-Velho, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Pedro Barata, Guru Sonpavde, Evan Y. Yu, Jonathan L. Wright, Petros Grivas, Ali Raza Khaki
Summary: The study compared clinical outcomes in patients with advanced urothelial carcinoma receiving programmed-death ligand-1 immune checkpoint inhibitors who had undergone radical surgery or radiation therapy prior to developing metastatic disease. It found that prior radical surgery was associated with better outcomes in the second-plus-line setting, including higher observed response rate, longer overall survival, and progression-free survival.
Article
Oncology
Albert Jang, Ellen B. Jaeger, Elisa M. Ledet, John Xie, Brian E. Lewis, Jodi L. Layton, Oliver Sartor, Pedro C. Barata, Christopher R. Trevino
Summary: This study found that prostate cancer rarely spreads to the central nervous system. Out of 579 patients with extracranial metastatic prostate cancer, 12 patients were identified to have CNS metastases based on imaging, including six patients with brain metastases. There was no statistically significant difference in survival between patients with CNS metastases and those without after the development of extracranial metastases.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Akram M. Shayeb, Hannah Dzimitrowicz McManus, Danielle Urman, Chinmay Jani, Tian Zhang, Nazli Dizman, Luis Meza, Akhilesh Sivakumar, Chun L. Gan, Pedro Barata, Mehmet A. Bilen, Xin Gao, Daniel Heng, Sumanta Pal, Ravi Narra, Deepak Kilari, Marina D. Kaymakcalan, Bradley McGregor, Toni K. Choueiri, Rana R. McKay
Summary: In this retrospective multicenter study, the safety of cabozantinib with different anticoagulants in patients with advanced RCC was investigated. The study found that DOACs appear to be safe for VTE treatment in patients on cabozantinib without increasing the risk of major bleeding events. Optimized anticoagulation management remains vital in clinical practice.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Justin Swaby, Ankita Aggarwal, Akshee Batra, Anubhav Jain, Lakshya Seth, Nickolas Stabellini, Marcio Sommer Bittencourt, Darryl Leong, Zachary Klaassen, Pedro Barata, Nicolas Sayegh, Neeraj Agarwal, Martha Terris, Avirup Guha
Summary: An updated meta-analysis reveals that androgen deprivation therapy (ADT) is not associated with the development of metabolic syndrome (MetS) and the association with diabetes is weaker than previously reported. However, ADT is associated with a 30% increased risk of hypertension.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Pedro C. Barata, Andrea Leith, Amanda Ribbands, Rachel Montgomery, Matthew Last, Bhakti Arondekar, Jasmina Ivanova, Alexander Niyazov
Summary: This study analyzed the real-world treatment trends for patients with metastatic castration-sensitive prostate cancer (mCSPC) between 2016 and 2020 in 5 European countries and the US. The results showed that more patients received treatment intensification with novel hormonal therapy and taxane chemotherapy in 2019-2020 compared to 2016-2018. In the US, greater use of treatment intensification with novel hormonal therapy was observed for all ethnicity groups and those with Medicare and commercial insurance status in 2019-2020. Further research is needed to understand optimal treatment sequencing in mCSPC and mCRPC.
Article
Oncology
Pedro C. Barata, Alexander Chehrazi-Raffle, Kimberly D. Allman, Aviva Asnis-Alibozek, Vijay Kasturi, Sumanta K. Pal
Summary: This article reports on the efficacy of Tivozanib in histologically diverse non-clear cell renal cell carcinoma. The study found that Tivozanib demonstrated activity and a favorable safety profile in patients with non-clear cell renal cell carcinoma, adding to the evidence supporting the use of VEGFR-TKI in this type of cancer.
Article
Oncology
Pedro C. Barata, Andrea Leith, Amanda Ribbands, Rachel Montgomery, Matthew Last, Bhakti Arondekar, Jasmina Ivanova, Alexander Niyazov
Summary: The study evaluated the impact of novel hormonal therapy (NHT) and docetaxel use in metastatic castration-sensitive prostate cancer (mCSPC) on first-line treatment patterns in metastatic castration-resistant prostate cancer (mCRPC). The results suggest that physicians consider mCSPC treatment history when making first-line treatment decisions in mCRPC.
Review
Oncology
Diana C. Simao, Kevin K. Zarrabi, Jose L. Mendes, Ricardo Luz, Jorge A. Garcia, William K. Kelly, Pedro C. Barata
Summary: Cancer treatments have changed with the introduction of immunotherapy, and new agents that redirect T-cells against cancer are rapidly emerging in multiple tumor types. However, the development of immunotherapy strategies remains a challenge in prostate cancer due to its heterogeneous and immune-suppressive tumor microenvironment.
Article
Oncology
Justine Panian, Ava Saidian, Kevin Hakimi, Archana Ajmera, William J. Anderson, Pedro Barata, Stephanie Berg, Sabina Signoretti, Steven Lee Chang, Vincent D'Andrea, Daniel George, Hannah Dzimitrowicz, Talal El Zarif, Hamid Emamekhoo, Evan Gross, Deepak Kilari, Elaine Lam, Isabel Lashgari, Sarah Psutka, Grant P. Rauterkus, Ahmed Shabaik, Bicky Thapa, Luke Wang, Nicole Weise, Kendrick Yim, Tian Zhang, Ithaar Derweesh, Rana R. McKay
Summary: This study analyzed the pathological outcomes of advanced or metastatic renal cell carcinoma patients who received immunotherapy prior to cytoreductive nephrectomy. The results showed that cytoreductive nephrectomy after immunotherapy is effective, but further prospective studies are needed to evaluate its role in the era of immunotherapy.
Article
Oncology
Diana Simao, Pedro C. Barata, Marta Alves, Ana L. Papoila, Sonia Oliveira, Peter Lawlor
Summary: This study assessed the stability of symptom clusters during disease progression and their association with survival in advanced cancer patients. Three distinct symptom clusters were identified: neuro-psycho-metabolic, gastrointestinal, and sleep impairment. The presence of the neuro-psycho-metabolic cluster and hospitalization were independently associated with worse survival.
Review
Oncology
Sree M. Lanka, Nicholas A. Zorko, Emmanuel S. Antonarakis, Pedro C. Barata
Summary: The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape of several genitourinary malignancies, but the utility of immunotherapies in prostate cancer has been limited due to its immunologically cold tumor terrain. Pembrolizumab is currently the only approved ICI for metastatic castration resistant prostate cancer (mCRPC) in a select group of patients. Future research is exploring combination approaches with ICIs and other treatments to enhance their efficacy in mCRPC. Additionally, alternative checkpoint inhibitors like B7-H3 hold promise in expanding the treatment options for mCRPC.
Review
Oncology
Albert Jang, Sree M. Lanka, Hui Ting Ruan, Hamsa L. S. Kumar, Angela Y. Jia, Jorge A. Garcia, Omar Y. Mian, Pedro C. Barata
Summary: This article provides an overview of novel therapies for metastatic prostate cancer, focusing on ongoing clinical trials. The future for patients with metastatic prostate cancer is promising, with the development of new therapies such as radiopharmaceuticals. Novel agents are being designed to overcome resistance to approved therapies, and combination therapies are being tested to improve outcomes for advanced prostate cancer patients.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Review
Biotechnology & Applied Microbiology
Albert Jang, Jake N. Lichterman, Jeffrey Y. Zhong, Jonathan E. Shoag, Jorge A. Garcia, Tian Zhang, Pedro C. Barata
Summary: This review discusses the next generation of immune approaches for locally advanced and metastatic renal cell carcinoma (RCC), including cytokines, gut microbiota-based therapies, novel immune checkpoint agents, vaccines, and chimeric antigen receptor T cells. These approaches, evaluated as monotherapy or in combination with traditional immune checkpoint inhibitors (ICIs), hold promise for improving outcomes in RCC patients.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Endocrinology & Metabolism
Channing J. Paller, Pedro C. Barata, Justin Lorentz, Leonard J. Appleman, Andrew J. Armstrong, Tiffani A. DeMarco, Robert Dreicer, Jo Ann B. Elrod, Mark Fleming, Christopher George, Elisabeth I. Heath, Maha H. A. Hussain, Shifeng Mao, Rana R. McKay, Alicia K. Morgans, Matthew Orton, Roberto Pili, Elyn Riedel, Biren Saraiya, Joelle Sigmond, Alexandra Sokolova, Walter M. Stadler, Christina Tran, Natalie Macario, Jacob Vinson, Rebecca Green, Heather H. Cheng, PROMISE Trial Investigators
Summary: The PROMISE Registry is a novel prospective germline registry aiming to collect long-term patient outcomes data, addressing gaps in understanding resulting from recent updates in treatment approaches and genetic testing recommendations for prostate cancer. By including a broad nationwide sample, including underserved patients and those unaffiliated with major academic centers, the registry aims to provide access to germline genetic testing and collect data to understand disease characteristics and treatment responses for prostate cancer with rare germline genetic variants.